World Vaccine Congress Europe 2026 has ended. This guide stays up as the record of who was there. Next: WVC Europe 2027, Oct 25–27, 2027 in Lyon

Cancer and therapeutic vaccines at World Vaccine Congress Europe 2026

Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website

18 organizations at World Vaccine Congress Europe 2026 present work in cancer & therapeutic vaccines: 6 vaccine and drug developers, 5 suppliers and service providers, 4 academic bodies and 3 public-health and non-profit bodies. Between them they bring 47 presentations to the program. Most represented: Sanofi, University of Oxford and European Medicines Agency. As of Oct 12, 2026.

All 268 organizations at World Vaccine Congress Europe 2026 →

Format
Top represented
Showing 1–10 of 18 organizations
OrganizationWorld Vaccine Congress Europe 2026 Attendance
Sanofi
Paris, France
Large pharma
Global pharmaceutical company with a large vaccines business spanning influenza, pediatric, meningitis and mRNA programs.
Talk
Mon Oct 19
10:45
mRNA-LNP Platform: Screening, Formulation Optimization and Process Improvements
Workshop: Platform Technologies
Talk
Mon Oct 19
11:30
Immunity Takes Care of Your Skin: The Vaccine Reinventing Acne Treatment
Workshop: Cancer & Therapeutic Vaccines
Talk
Mon Oct 19
14:45
Assessing and Monitoring Vaccine Safety in the AI Era
Workshop: Vaccine Safety & Access
Talk
Mon Oct 19
15:30
Advancing Pandemic Preparedness: Pandemic Flu H5 mRNA program
Workshop: Biothreats & Disease X
Talk
Tue Oct 20
09:00
The Technology Revolution: Agility for the Wave of Next Generation Vaccines
Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease.
with European Medicines Agency, Vaccines Europe, International Vaccine Institute +4 more
Platforms & delivery
Talk
Wed Oct 21
12:45
Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development
Why vaccine development has slowed back to pre-pandemic speeds and which changes, including AI, could make clinical trials faster.
with PATH, McKinsey & Company, AstriVax
Talk
Wed Oct 21
13:30
Platform leverage in vaccine development: how diversified technologies and adjuvant innovation are reshaping protection for older adults,
Respiratory
Talk
Wed Oct 21
15:00
Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling
Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them.
with GSK, Swedish Medical Products Agency, European Medicines Agency
Talk
Mon Oct 19
10:00
Workshop Leader’s Opening Remarks
Workshop: Platform Technologies
Talk
Mon Oct 19
11:45
Talk
Tue Oct 20
16:30
Panel
Tue Oct 20
17:00
One Health in Action: Connecting Human, Animal, and Environmental Health to Advance Vaccine Strategy
How tracking disease in people, animals and the environment together can set vaccine priorities for infections that jump from animals, like bird flu.
with Food and Agriculture Organization (FAO), Lyonbiopole, Health Emergency Preparedness and Response Authority +1 more
One Health & ecosystems
Talk
Wed Oct 21
10:30
From crisis to preparedness: vaccine development during and between outbreaks lessons from the Bundibugyo virus (BDBV) PHEIC
Emerging & Infectious Diseases
Panel
Wed Oct 21
10:45
Panel: Emerging Outbreaks at the Front Line: From Early Signals to Real-World Response
How outbreaks like bird flu and hantavirus can be spotted sooner, what vaccines add to the response, and where gaps remain.
with UK Health Security Agency (UKHSA), CSL Seqirus, GSK +1 more
Talk
Wed Oct 21
14:30
Neutralising antibody is a poor predictor of protection by candidate EBV vaccines
Emerging & Infectious Diseases
European Medicines Agency
Amsterdam, Netherlands
Public health & non-profit
The European Union's medicines regulator, evaluating and monitoring vaccines and medicines.
Panel
Mon Oct 19
12:15
Panel: Chronic Conditions and Off-target Effects of Vaccines
Whether vaccines like those for tuberculosis, measles and shingles affect unrelated infections, asthma or dementia, and how trials could measure it.
with Vaxxcellence, Harvard Medical School, Total Trials +1 more
Panel
Mon Oct 19
14:15
Panel: From Non-Inferiority to Impact: Accelerating Adoption of Needle-Free Vaccine Delivery
Why common doubts about needle-free vaccine delivery, such as cost, regulation and patient uptake, may no longer hold up.
with Daicel Life Sciences, PharmaJet, LTS Lohmann +2 more
Talk
Mon Oct 19
15:00
Panel: Global Vaccine Access: Balancing Speed and Safety
How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks.
with GSK, BioNTech, Gates Medical Research Institute +1 more
Talk
Tue Oct 20
09:00
The Technology Revolution: Agility for the Wave of Next Generation Vaccines
Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease.
with Vaccines Europe, International Vaccine Institute, Eli Lilly +4 more
Platforms & delivery
Talk
Wed Oct 21
12:00
Working Group: Quality Communication for Vaccine Literacy and Uptake
Practical ways organizations can communicate clearly about vaccines to build trust and help people make informed decisions.
with Eli Lilly, Pfizer, CUNY School of Public Health +1 more
Supply, safety & access
Talk
Wed Oct 21
15:00
Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling
Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them.
with GSK, Swedish Medical Products Agency, Sanofi
BioNTech
Mainz, Germany
Large pharma
Develops mRNA vaccines and immunotherapies for infectious diseases and cancer, including the marketed COVID-19 vaccine Comirnaty.
Talk
Mon Oct 19
10:15
Multi-Modality approaches in immuno-oncology: navigating regulatory hurdles to shape the future of cancer therapies
Workshop: Cancer & Therapeutic Vaccines
Talk
Mon Oct 19
15:00
Panel: Global Vaccine Access: Balancing Speed and Safety
How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks.
with GSK, European Medicines Agency, Gates Medical Research Institute +1 more
Talk
Wed Oct 21
12:30
Design and development of mRNA-encoded tuberculosis vaccines
AMR & Bacterial Vaccines
BiotechBronze sponsor
Uses its AI-Immunology platform to discover and design vaccines against bacterial and viral infections and cancer.
Booth
Exhibiting at Booth 216
Talk
Wed Oct 21
11:00
AI-Immunology™-Powered Development of Vaccines Against Bacterial Infections
AMR & Bacterial Vaccines
Talk
Wed Oct 21
11:30
AI-Immunology for the discovery and design of novel vaccine targets
Emerging & Infectious Diseases
SB
Sagitta Biotech
Biotech
Develops targeted viral vectors that deliver toxic payloads to solid tumors, with efficacy data in glioblastoma.
Talk
Wed Oct 21
10:40
Panel
Mon Oct 19
12:15
Panel: Chronic Conditions and Off-target Effects of Vaccines
Whether vaccines like those for tuberculosis, measles and shingles affect unrelated infections, asthma or dementia, and how trials could measure it.
with Harvard Medical School, European Medicines Agency, Total Trials +1 more
Session
Tue Oct 20
14:00
Track Chair
Immune Profiling
Session
Tue Oct 20
16:00
Track Chair
Immune Profiling
Talk
Mon Oct 19
10:30
Standardized Serology: A Critical Foundation for HPV Vaccine Development and Implementation
Workshop: Cancer & Therapeutic Vaccines
Session
Tue Oct 20
14:00
Track Chair
Pre-Clinical Development
Session
Tue Oct 20
16:00
Track Chair
Pre-Clinical Development
CRO, CDMO & labs
Vaccine-focused contract research organization, formerly FHI Clinical, offering research, development and partnering services to vaccine makers.
Booth
Exhibiting at Booth 237
Panel
Mon Oct 19
12:15
Panel: Chronic Conditions and Off-target Effects of Vaccines
Whether vaccines like those for tuberculosis, measles and shingles affect unrelated infections, asthma or dementia, and how trials could measure it.
with Vaxxcellence, Harvard Medical School, European Medicines Agency +1 more
Talk
Wed Oct 21
14:15
EBV
Emerging & Infectious Diseases
Academic
Institute of Heidelberg University Hospital researching global health, health systems and disease prevention.
Talk
Mon Oct 19
12:00
Panel
Mon Oct 19
12:15
Panel: Chronic Conditions and Off-target Effects of Vaccines
Whether vaccines like those for tuberculosis, measles and shingles affect unrelated infections, asthma or dementia, and how trials could measure it.
with Vaxxcellence, Harvard Medical School, European Medicines Agency +1 more

Explore the full World Vaccine Congress Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Amsterdam. Leave your work email and we’ll be in touch.

Privacy

Download the full World Vaccine Congress Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers in cancer & therapeutic vaccines

Tell us what you sell and we’ll find the people at organizations working on cancer & therapeutic vaccines most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse World Vaccine Congress Europe 2026 by

Exhibit hall

Not affiliated with or endorsed by the World Vaccine Congress or its organizers. Submit a correction